- Investment supports growing demand for biopharmaceutical research
- Builds capabilities with two new manufacturing and distribution centers in South Korea and India
- Accelerates Mobius® single-use manufacturing in China for biosimilars development
Darmstadt, Germany, February 21, 2018 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced an additional investment of $47 million to build a robust manufacturing and distribution platform in Asia over a span of two years. This investment follows the company’s November 2016 announcement of its $95 million Life Science investment in Nantong, China.
“In biopharmaceutical research, time is of the essence,” said Udit Batra, CEO, Life Science. “Our investments in the important Asian markets of South Korea, India and China ensure that our customers have ready access to the products needed to develop new therapies and biosimilars that accelerate access to health for people everywhere.”
Manufacturing & Distribution Center in Songdo, South Korea
The rapidly growing biopharmaceutical industry in South Korea makes the country one of the key Life Science hubs in Asia. The push for research and for rapid, custom manufacturing capabilities mean a greater need for accessibility to pharmaceutical products and solutions toward the advancement of research and innovation. Merck KGaA, Darmstadt, Germany’s new manufacturing and distribution center, located in the Songdo district of Incheon, will include an infrastructure to facilitate the supply of its products to customers in Korea and advanced cell culture media manufacturing capabilities (imMEDIAte Advantage® Custom Media). Occupying a land area of 109,000 square feet, the new site is expected to be fully operational in Q4 2019.
New Manufacturing & Distribtion Center in Mumbai, India
The new manufacturing and distribution centr, located in Mumbai, is expected to be completed in 2019. Occupying 10 acres, the site is more than 129,000 square feet with added capacity to meet future growth, further improving inventory availability and reducing lead times.
Mobius® Single-use Manufacturing in Wuxi, China
China, with a burgeoning biosimilar market, is fast becoming a biotech powerhouse. Single-use technologies provide increased flexibility and efficiency which are critical for biosimilar development and manufacturing. This investment, to accelerate Merck KGaA, Darmstadt, Germany’s Mobius® single-use manufacturing, addresses the growing biopharmaceutical demand in China. The site will be ready in 2018, and is expected to reduce lead time by at least 50 percent.